Recent News 89 : Cytophage Receives Federal Support for Entry into European Market through France Biomanufacturing Mission

-

Cytophage Receives Federal Support for Entry into European Market through France Biomanufacturing Mission

WINNIPEG, September 29, 2025 — Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV: CYTO, FSE: 70G) announced its participation in the Canadian biomanufacturing mission held in Lyon and Paris, France from September 21-25, 2025 under the Canadian International Innovation Program (CIIP). This government-led initiative, organized by Global Affairs Canada and the National Research Council of Canada, brought together leading Canadian companies to explore co-innovation opportunities within the French bioeconomy.

“We engaged with prospective European partners on this mission to help advance the commercialization of our bacteriophage products globally,” said Dr. Steven Theriault, CEO of Cytophage. “We were honoured to represent Canadian innovation alongside our esteemed industry peers, and grateful for the federal government’s support for this mission. We extend our sincere thanks to the Trade Commissioner Service | Service des délégués commerciaux of Canada and the Canadian International Innovation Program (CIIP) for making this initiative possible.”

Participation in this mission allowed Cytophage to showcase its innovative bacteriophage products for human and animal health, most notably at the 10th Bioproduction Congress in Lyon, France which is Europe’s premier biopharmaceutical manufacturing event. The Company’s participation included one-on-one meetings and numerous networking opportunities aimed at establishing new biomanufacturing partnerships, and accelerating the Company’s entry into the EU market. The program also featured high-level visits with French industry leaders, University Hospitals and innovation clusters.

Cytophage will advance discussions with leading European animal health companies regarding distribution opportunities for its animal health bacteriophage products following the recent completion of successful pilot studies in Europe (see September 23, 2025 press release). Cytophage will also explore larger-scale R&D collaborations identified from meetings during the mission as it works to continue leveraging its proprietary bacteriophage design platform to drive international growth.

The government’s inclusion of Cytophage in this mission underscores federal support and recognition for the Company’s leadership in bacteriophage technology and its potential to address the urgent global challenge of antimicrobial resistance.



In addition to Cytophage’s first EU pilot study earlier this summer where effective E. coli containment and decreased mortality were observed, this study’s findings further validate AviPhage’s commercial potential as a next-generation solution for poultry producers seeking to reduce antibiotic use while maintaining or enhancing productivity.

Next Steps 

The results of this study advance Cytophage’s goal to secure regulatory approval and product registration across the EU. The studies have demonstrated product efficacy and the capacity of the AviPhage to replace antibiotics within the working barn setting. More studies will be required for the broader EU regulatory application.  At the same time, the Company is continuing its efforts to further validate AviPhage’s effectiveness in the global market.


Copyright belongs to for article and photo, taken from : https://cytophage.com/news/cytophage-receives-federal-support-for-entry-into-european-market-through-france-biomanufacturing-mission/



Comments

Post a Comment

Popular posts from this blog

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Paper 3 : Phage Therapy May Treat Drug Resistance in Patients With Cystic Fibrosis, Study Finds

-
Image
Phage Therapy May Treat Drug Resistance in Patients With Cystic Fibrosis, Study Finds June 13, 2025 "Yale's university researchers find a new approach to combatting antimicrobial resistance. Antimicrobial resistance, in which germs like bacteria and fungi no longer respond to medicines, is a rising global threat. When antibiotics and other drugs become ineffective, infections can become difficult or impossible to treat, leading to an increase in the spread and severity of disease. In a new study, published in Nature Medicine , a team of researchers at the Center for Phage Biology and Therapy at Yale discovered a novel approach that may revolutionize the fight against antimicrobial resistance. Jon Koff, MD, with a patient Credit: Robert A. Lisak For the study, the research team investigated the use of phage therapy—the use of viruses, or phages, to target and kill bacteria—to help patients with cystic fibrosis, a disease in which antimicrobial resistance is a significant issue....
Read more